-
Robert Hatcher, MD, MPH, professor of obstetrics and gynecology at Atlanta's Emory University and chairman of the editorial board for Contraceptive Technology Update, is the 2007 recipient of the Kenneth J. Ryan, MD, Physician Leadership Award.
-
Clinicians now have a dedicated continuous use oral contraceptive. The Food and Drug Administration (FDA) has given final approval to Lybrel from Wyeth Pharmaceuticals of Collegeville, PA. The drug represents the first combination contraceptive pill designed to be taken 365 days a year, without a placebo phase or pill-free interval.
-
In 1997, federal block grant funding for abstinence-only sexuality education went into effect. Despite limited research on the efficacy of such programs, many states applied for a portion of the $50 million in federal dollars.
-
The next patient in your exam room is a young female adolescent. How can you help motivate her when it comes to condom use?
-
As the first year of the two-year 110th Congress gets under way the first time in a dozen years that Democrats have been in charge of both chambers reproductive health advocates are working with a sense of cautious optimism.
-
Get ready to tackle a resurgence of syphilis among males who have sex with males (MSM). Results from a new study indicate that increasing syphilis cases among this population group account for most of the recent overall increase in national syphilis rates and may be a harbinger of increasing rates of HIV infection among MSM.
-
HIV isn't contained to one age bracket. Many patients diagnosed with HIV in the 1980s and 1990s have survived and now are entering their golden years.
-
The Centers for Disease Control and Prevention joins with other governmental and nongovernmental prevention partners in orchestrating the conference.
-
How can providers ease fears when it comes to vasectomy? Take a look at no-needle, no-scalpel vasectomy (NSV), which utilizes a jet injector to spray an anesthetic solution through the skin and around the vas prior to no-scalpel vasectomy.
-
I am writing to provide important details from the Today contraceptive sponge worldwide Phase III clinical trial that were not presented in your recent article in Contraceptive Technology Update.
